Press Releases & Presentations

Press Releases & Presentations

Date Title and Summary Additional Formats
Toggle Summary Accelerate Diagnostics Achieves CE-IVD Milestone for ID/AST System and ID/AST Blood Culture Assay
TUCSON, Ariz. , June 30, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. , announced today its declaration of conformity to the European In Vitro Diagnostic Directive 98/79 EC and CE Mark of the Accelerate ID/AST System and ID/AST Blood Culture Assay for in vitro diagnostic use. Read more
View HTML
Toggle Summary Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4
TUCSON, Ariz. , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today its declaration of conformity to the European In Vitro Diagnostic Directive 98/79/EC and CE mark of its latest assay for the Accelerate Phenoâ„¢ system targeting severe bacterial pneumonia infections. Read more
View HTML
Toggle Summary Accelerate Diagnostics Achieves ISO 13485 Certification and Initial Installations of Accelerate ID/AST System
TUCSON, Ariz. , March 16, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc . (Nasdaq:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms, announced today that it received ISO 13485:2003 certification for its quality Read more
View HTML
Toggle Summary Accelerate Diagnostics Announces Closing of $79.3 Million Upsized Offering
TUCSON, Ariz. , May 15, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced the closing of its previously announced underwritten public offering of 2,750,000 shares of its common stock today, upsized from the original share offering of 2,500,000 shares of common stock, at Read more
View HTML
Toggle Summary Accelerate Diagnostics Announces Final Results of Rights Offering
TUCSON, Ariz. , May 2, 2014 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), announced today that it has completed its previously announced rights offering. Through broad participation from both insiders and non-insider investors, together with funds committed through the related Read more
View HTML
Toggle Summary Accelerate Diagnostics Announces Final Results of Rights Offering
Accelerate Diagnostics Announces Final Results of Rights Offering TUCSON, Ariz., Aug. 13, 2013 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX), announced today that it has completed its previously announced rights offering. Through broad participation from both insiders and non-insider Read more
View HTML
Toggle Summary Accelerate Diagnostics Announces Final Terms of Rights Offering
Company previously announced plans to raise $20,000,000 to fund product commercialization efforts Read more
View HTML
Toggle Summary Accelerate Diagnostics Announces New Leadership Appointments
TUCSON, Ariz. , April 17, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. , an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms, announced today that it has appointed Ron Price as Senior Vice President and Head of Read more
View HTML
Toggle Summary Accelerate Diagnostics Announces Plans For Rights Offering To Stockholders
Accelerate Diagnostics Announces Plans For Rights Offering To Stockholders TUCSON, Ariz., June 4, 2013 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired Read more
View HTML
Toggle Summary Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock
TUCSON, Ariz. , Dec. 9, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced the pricing of an underwritten public offering of 5,588,236 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being sold by Accelerate Diagnostics Read more
View HTML
:

Day High:
Day Low:  
Volume:    

Copyright Nasdaq. Minimum 15 minutes delayed.


Want to receive investor-related news and updates?

Join our mailing list

Other updates